Dofetilide: first of a new generation of class III agents

Bibliography

• THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL (CAST) INVESTIGATORS: Effects of encainide and flecainide on mortality in a randomised trial of arrhythmia. NewEngl. J. Med. (1989) 21:406–412.
   Google Scholar
• DOWNAR E, HARRIS L, MICKLEBOROUGH LL et al.: Endo-cardial mapping of ventricular tachycardia in the intact human ventricle. Evidence for re-entrant mechanisms. Am. Coll. Cardiol. (1988) 11:783–791.
   PubMed Web of Science ®Google Scholar
• GWILT M, ARROWSMITH JE, BLACKBURN KJ et al: A novel, potent and highly selective class III anti-arrhythmic agent which blocks potassium channels in cardiac cells. Pharmacol. Exp. Ther. (1991) 256:318–324.
   PubMed Web of Science ®Google Scholar
• Description of basic electrophysiology.
   Google Scholar
• SEDGEWICK MJ, RASMUSSEN HS, WALKER D, COBBE SM: Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class Ill anti-arrhythmic drug. Br. J. Clin. Pharmacol (1991) 31:515–519.
   PubMed Web of Science ®Google Scholar
• SMITH DA, RASMUSSEN HS, STOPHER DA, WALKER DK: Pharmacokinetics and metabolism of dofetilide in mouse, rat, and man. Xenobiotica (1992) 22:709–719.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN HS, ALLEN MJ, BLACKBURN KJ, BUTROUS GS, DALRYMPLE HW: Dofetilide, a novel class Ill anti-ar-rhythmic agent. J. Cardiovasc. Pharmacol. (1992) 20:S96–105.
   PubMed Web of Science ®Google Scholar
• THAM TCK, MACLENNAN BA, HARRON DWG eta].: Phar-macodynamics and pharmacokinetics of the novel class III anti-arrhythmic drug UK-68,798 in man. Br. J. Clin. Pharmacol. (1991) 31:243P–244P.
   Google Scholar
• WALKER DK, ALABASTER CT, CONGRAVE GS et al.: Signifi-cance of metabolism in the disposition and action of the antidysrhythrnic drug dofetilide. In vitro studies and correlation with in vivo data. Drug Metab. Dispos. (1996) 24:447–455.
   PubMed Web of Science ®Google Scholar
• WALKER DK, ALABASTER CT, CONGRAVE GS, JONES BC, SMITH DA: Formation, physical properties and pharma-cological activity of the metabolites of dofetilide: in vitro studies. Br. J. Clin. Pharmacol (1994) 37:499P.
   Google Scholar
• SEDGEWICK MJ, RASMUSSEN HS, COBBE SM: Effects of the class Ill anti-arrhythmic drug dofetilide on ventricu-lar monophasic action potential duration and QT inter-val dispersion in stable angina pectoris. Am. J. Cardiol (1992) 70:1432–1437.
   PubMed Web of Science ®Google Scholar
• GWILT M, KING RC, MILNE AA, SOLCA AM: Dofetilide, a new class Ill anti-arrhythmic agent, reduces pacing-in-duced heterogeneity of repolarisation in vivo. Cardiovasc. Res. (1992) 26:1102–1108.
   PubMed Web of Science ®Google Scholar
• Differential effects of dofetilide on repolarisation with relevance to its anti-arrhythmic activity.
   Google Scholar
• BASKIN EP, SERIK CM, WALLACE AA eta].: Effects of new and potent methanesuffonanilide class III anti-arrhyth-mic agents on myocardial refractoriness and contrac-tility in isolated cardiac muscle.J. Cardiovasc. Pharmacol (1991) 18:406–414.
   Google Scholar
• YANG T, TANDE PM, LATHROP DA, REFSUM H: Preven-tion of hypoxia-induced action potential shortening and reduction of contractile force by UK-68798. Circu-lation (1991) 84(4 Suppl.
   Google Scholar
• TVVEEDIE D, HENDERSON C, KANE K: Glibenclamide, but not class Ill drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts. Eur. J. Phar-macoL (1993) 240:251–257.
   PubMed Web of Science ®Google Scholar
• MONTERO M, SCHMITT C: Recording of transmembrane action potentials in chronic ischaemic heart disease and dilated cardiomyopathy and the effects of the new class III anti-arrhythmic agents D-sotalol and dofetilide. J. Cardiovasc. Pharmacol. (1996) 27:571–577.
   PubMed Web of Science ®Google Scholar
• HONDEGHEM LM, SNYDERS DJ: Class III anti-arrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use de-pendence. Circulation (1990) 81:686–690.
   PubMed Web of Science ®Google Scholar
• TODT H, ZOJER N, SCHUTZ W: Differential effect of dofetilide on ventricular repolarizarion during steady state and during restituion in vivo. J. Cardiovasc. Phar-macoL (1994) 24:1010–1013.
   PubMed Web of Science ®Google Scholar
• SEDGEWICK MJ, LIP G, REA AP, COBBE SM: Chemical cardioversion of atrial fibrillation with intravenous dofetilide. mt. J. Cardiol. (1995) 49:159–166
   Web of Science ®Google Scholar
• YANG T, TANDE PM, LATHROP DA, RASMUSSEN HS: Effects of altered extracellular potassium and pacing cycle length on the class III anti-arrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle. Cardiovasc. Drugs Ther. (1992) 6:429–436.
   PubMed Web of Science ®Google Scholar
• NOBLE D, TSIEN RW: Outward currents activated in the plateau range of potential in cardiac Purkinje fibres. J. Physiol. (London) (1969) 200:205–231.
   Google Scholar
• SANGUINETTI MC, JURKIEWICZ NK: Two components of cardiac delayed rectifier K current: differential sensitiv-ity to block by class III anti-arrhythmic agents. J. Gen. Physiol. (1990) 96:195–215.
   PubMed Web of Science ®Google Scholar
• CARMELIET E: Voltage- and time- dependent block of the •delayed K current in cardiac myocytes by dofetilide. J.Pharmacol Exp. Ther. (1992) 809–817.
   PubMed Web of Science ®Google Scholar
• Voltage clamp study of Ik and the ionic changes caused by dofetilide.
   Google Scholar
• JURKIEWICZ NK, SANGUINETTI MC: Rate-dependent pro-longation of cardiac action potentials by a methanesul-fonanilide class Ill anti-arrhythmic agent. Specific block of rapidly activating delayed rectifier K current by dofetilide. Circ. Res. (1993) 72:75–83.
   Google Scholar
• KRAFTE DS, VOLBERG WA: Voltage dependence of car-diac delayed rectifier block by methanesulfonamide class III anti-arrhythmic agents. I. Cardiovasc. Pharma-col. (1994) 23:37–41.
   PubMed Web of Science ®Google Scholar
• BASKIN EP, LYNCH JJ: Comparative effects of increased extracellular potassium and pacing frequency on the class III activities of methanesulfonanilide (kr) block-ers dofetilide, d-sotalol, E-4031, and MK-499. J. Cardiovasc. Pharmacol (1994) 24:199–208.
   PubMed Web of Science ®Google Scholar
• CHADWICK CC, EZRIN AM, O'CONNOR B et al: Identifi-cation of a specific radioligand for the rapidly activating delayed rectifier K channel. Circ. Res. (1993) 72:707–714.
   PubMed Web of Science ®Google Scholar
• YANG T, WATHEN MS, FELIPE A et al.: K currents and K channel messenger-RNA in cultured atrial cardiac myo-cytes (AT-1 cells). Circ. Res. (1994) 75:870–878.
   PubMed Web of Science ®Google Scholar
• SNYDERS DJ, CHOUDHARY A: High affinity open chan-nel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol (1996) 49:949–955.
   PubMed Web of Science ®Google Scholar
• KIEHN J, LACERDA AE, WIBLE B, BROWN AM: Molecular physiology and pharmacology of HERG. Circulation (1996) 94:2572–2579.
   PubMed Web of Science ®Google Scholar
• KIEHN J, WIBLE B, LACERDA AE, BROWN AM: Mapping of the block of a cloned human inward rectifier potassium channel by dofetilide. Mol Pharmacol. (1996) 50:380–387.
   PubMed Web of Science ®Google Scholar
• YANG T, TANDE PM, REFSUM H: Negative chronotropic effect of a novel class III anti-arrhythmic drug, UK-68,798, devoid of beta-blocking action on isolated guinea-pig atria. Br. J. Pharmacol (1991) 103:1417–1420.
   PubMed Web of Science ®Google Scholar
• WALLACE AA, STUPIENSKI III RF, BROOKES LM et al: Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III anti-ar-rhythmic agents in anaesthetised dogs. J. Cardiovasc. Pharmacol (1991) 18:687–695.
   PubMed Web of Science ®Google Scholar
• SERIK C, BASKIN E, WIEDMANN R: Inotropic effects of class Ill anti-arrhythmic agents in isolated ventricular myocardium [Abstract]. FASEB J (1990) 4:A455.
   Google Scholar
• REITER M: Calcium mobilisation and cardiac inotropic mechanisms. Pharmacol. Rev. (1988) 40:189–217.
   PubMed Web of Science ®Google Scholar
• MORTENSEN E, YANG T, REFSUM H: Class III anti-ar-rhythmic action and inotropy: effects of dofetilide in acute ischaemic heart failure in dogs. J. Cardiovasc. Pharmacol (1992) 19:216–221.
   PubMed Web of Science ®Google Scholar
• Preclinical study demonstrating the safety and maintained efficacy of dofetilide.
   Google Scholar
• GWILT M, KING RC, MILNE AA, SOLCA AM: Dofetilide, anew class III anti-arrhythmic agent, reduces pacing-in-duced heterogeneity of repolarisation in vivo. J. Cardiovasc. Res. (1992) 26:1102–1108.
   PubMed Web of Science ®Google Scholar
• BLACK SC, CHI LG, MU DX, LUCCHESI BR: The antifibril-latory actions of UK-68,79, a class Ill anti-arrhythmic agent. J. Pharmacol. Exp. Ther. (1991) 258:416–423.
   PubMedGoogle Scholar
• SEDGEWICK MJ, RASMUSSEN HS, COBBE SM: Clinical and electrophysiological effects of intravenous dofetilide (UK-68,798), a new class Ill anti-arrhythmic drug in patients with angina pectoris. Am. J. Cardiol (1992) 69:513–517.
   PubMed Web of Science ®Google Scholar
• KUO CS, ATARASHI H, REDDY CP, SURAWICZ B: Disper-sion of ventricular re pol arization and arrhythmia study of two consecutive ventricular premature complexes. Circulation (1985) 72:370–376.
   PubMed Web of Science ®Google Scholar
• DEMOLIS JL, FUNCK-BRENTANO C, ROPERS J et al.: Influ- ?ence of dofetilide on QT-interval duration and disper-sion at various heart rates during exercise in humans. Circulation (1996) 94:1592–1599.
   PubMed Web of Science ®Google Scholar
• Study demonstrating the absence of a significant concentration-de-pendent increase in QT interval dispersion in healthy subjects.
   Google Scholar
• ZUANETTI G, CORR PB: Anti-arrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocar-dial infarction: evaluation using three-dimensional mapping. J. Pharmacol Exp. Ther. (1991) 256:325–334.
   PubMed Web of Science ®Google Scholar
• LAD N, MACKENZIE I: Limited effect of class III agents against acute ischaemic arrhythmias in anaesthetised cats. J. MoL Cell. Cardiol. (1991) 23:S38.
   Google Scholar
• RAHIMTOOLA SH, ZIPES DP, AKHTER M et al.: Consensus statement of the conference on the state of the art of electrophysiological testing in the diagnosis and treat-ment of patients with cardiac arrhythmias. Circulation (1987) 75:1113–7.
   Google Scholar
• KIM SG, FEWER SD, FIGURA A et al: The prognostic value of the changes in the mode of ventricular tachycardia induction noted during therapy with amiodarone and a class Ia anti-arrhythmic agent. Am. J. Cardiol. (1987) 59:1314–1318.
   PubMed Web of Science ®Google Scholar
• ANDERSEN HR, WIGGERS H, KNUDSEN LL, THOMSEN PEB, CHRISTIANSEN N: Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischae-mia: a randomised study in pigs. Cardiovasc. Res. (1994) 28:1635–1640.
   PubMed Web of Science ®Google Scholar
• Demonstration of dofetilide's anti-arrhythmic efficacy in an animal model of VF.
   Google Scholar
• LYNCH JJ, WILBER DJ, MONTGOMERY DG eta].: Suppres-sion of lethal ischaemic ventricular arrhythmias by the class III agent E4031 in a canine model of previous myocardial infarction.' Mol. Cell. Cardiol. (1989) 21:S154.
   Google Scholar
• GREMILLION ST, ECHT DS, SMITH NA, KOPP D, WILBER D: Beneficial effects of intravenous dofetilide in pa-tients undergoing ventricular defibrillation testing [Ab-stract]. Circulation (1992) 86:1–264.
   PubMedGoogle Scholar
• ECHT DS, GREMILLION ST, LEE JT: Effects of procai-namide and lidocaine on defibrillation energy require-ments in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc. Electrophysiol. (1994) 5:752.
   PubMed Web of Science ®Google Scholar
• ECHT DS, LEE JT, MURRAY KT et al.: A randomized double-blind, placebo-controlled dose ranging study of intravenous UK 68,798 (dofetilide) in patients with inducible sustained ventricular tachyarrhythmias [Ab-stract]. Circulation (1991) 84:11–714.
   Google Scholar
• BASHIR Y, WONG C, NATHAN AW et al.: Efficacy and safety of dofetilide, a new class III anti-arrhythmic agent in recurrent ventricular tachycardia. Br. Heart J. (1992) 68:116.
   Google Scholar
• BASHIR Y, THOMSEN PE, KINGMA JH et al.: Electrophysi- ologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III anti-arrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. Am. J. Cardiol. (1995) 76:1040–1044.
   Web of Science ®Google Scholar
• Demonstration of dofetilide's anti-arrhythmic efficacy in humans.
   Google Scholar
• YUAN S, WOHLFART B, RASMUSSEN HS, OLSSON S, BLOM- STROM LC: Effect of dofetilide on cardiac repolarisation in patients with ventricular tachycardia: a study using simultaneous monophasic action potential recordings from two sites in the right ventricle. Eur. Heart J. (1994) 15:514–522.
   PubMed Web of Science ®Google Scholar
• BRACHMANN J, HAVERKAMP W, JOHNS J et al: The efficacy and safety of oral dofetilide in patients with sustained ventricular tachycardia [Abstract]. Circulation (1992) 86:1–265.
   PubMedGoogle Scholar
• BAILEY WM, NADEMANEE K, EDWARDS J et al.: Electro-physiologic and hemodynamic effects of dofetilide in patients with severe left ventricular dysfunction [Ab-stract]. Circulation (1992) 86:1–265.
   PubMedGoogle Scholar
• MOLLER M: Diamond anti-arrhythmic trials. Lancet (1996) 348:1597–1598.
   PubMed Web of Science ®Google Scholar
• FEW GK, CHA YM, SAWHNEY N: Termination and sup-pression of experimental canine atrial flutter by dofetilide: effects on dispersion of repolarisation and conduction velocity. J. Am. Coll. Cardiol. (1994) 23:443A.
   PubMedGoogle Scholar
• SCHOELS W, OFFNER B, FREIGANG KD etal: Termination of circus movement atrial flutter by the new type-III-agent dofetilide: differential effects on the components of the re-entrant pathway. J. Am. Coll. Cardiol (1994) 23:206A.
   Google Scholar
• TASK FORCE OF THE WORKING GROUP ON ARRHYTH-MIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY: The Sicilian Gambit. A new approach to the classification of anti-arrhythmic drugs based on their actions and ar-rhythmogenic mechanism. Circulation (1991) 84:1831–1851.
   Google Scholar
• CRIJNS HJGM, VANGELDER LC, KINGMA JH et al.: Atrial-flutter can be terminated by a class-III anti-arrhythmic drug but not by a class-IC drug. Eur. Heart J. (1994) 15:1403–1408.
   PubMed Web of Science ®Google Scholar
• GOSSELINK A, KOOISTRA M, KINGMA JH, DUNSELMAN P, DALRYMPLE HW: Efficacy and safety of intravenous dofetilide in atrial fibrillation or flutter. Circulation (1993) 88:396.
   Web of Science ®Google Scholar
• SINGH SN, FALK R, FRIEDRICH T, SINGH B: The efficacy and safety of dofetilide in patients with recent-onset atrial-fibrillation or flutter. Circulation (1993) 88:65.
   Web of Science ®Google Scholar
• SUTTORP MJ, POLAK PE, VAN'T HOF A et al.: Efficacy and safety of a new selective class III anti-arrhythmic agent, dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am. J. Cardiol. (1992) 19:216–221.
   Google Scholar
• Demonstration of dofetilide's efficacy in the termination of supra-ventricular arrhythmias.
   Google Scholar
• FROST L: Efficacy and safety of dofetilide, a new class III anti-arrhythmic agent in acute termination of atrial fibrillation or flutter after coronary artery bypass sur-gery. Int. Cardiol. (1997) 58:135–140.
   PubMed Web of Science ®Google Scholar
• CONELLY DT, THOMSEN PEB, CAMM AJ: Efficacy and safety of dofetilide, a novel class III agent in atrioven- tricular nodal re-entrant tachycardia. Eur. HeartJ (1992) 18:304.
   Google Scholar
• WONG CKY, HEALD S, THOMSEN PEB: Electrophysiol-ogy, safety and efficacy of dofetilide in patients with atrioventricular re-entrant tachycardia. Eur. Heart J. (1992) 18:211.
   Google Scholar
• JORDAENS L, GORGELS A, STROOBRANDT R, TEMMER-MAN J: Efficacy and safety of intravenous sotalol for the termination of paroxysmal supraventricular tachy-cardia. The Sotalol versus Placebo Multicentre Study Group. Am. J. Cardiol. (1991) 68:35–40.
   Google Scholar
• MIWA S, INOUE T, OGAWA H, FUJIMOTO T, OHNISH1 Y: Monophasic action potential in patients with torsades de pointes. Circulation (1989) 80:11–660.
   Google Scholar
• CARLSSON L, ALMGREN O, DUKER G: QTU-prolongation and torsades de pointes induced by putative class III anti-arrhythmic agents in the rabbit: aetiology and interventions. J. Cardiovasc. Pharmacol. (1990) 16:276–285.
   PubMed Web of Science ®Google Scholar
• BUCHANAN LV, KABELL G, BRUNDEN MN, GIBSON JK:Comparative assessment of ibutilide, d-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of pro-arrhythmia. J. Cardiovasc. Pharmacol. (1993) 22:540–549.
   PubMed Web of Science ®Google Scholar
• STRATMAN HG, KENNEDY HL: Torsades de pointes asso-ciated with drugs and toxins: recognition and manage-ment. Am. Heart J. (1987) 113:1470–1482.
   PubMed Web of Science ®Google Scholar
• KATRISTSIS D, CAMM AJ: New class III antiarrhythmic drugs. Eur. Heart J. (1993) 14:93–99.
   Web of Science ®Google Scholar
• ABRAHAMSSON C, PALMER M, LJUNG B et al.: Induction of rhythm abnormalities in the fetal rat heart. A tenta-tive mechanism for the embryotoxic effect of the class III anti-arrhythmic agent almokalant. Cardiovasc. Res. (1994) 28:337–344.
   Google Scholar
• BAN Y, KONISH1 R, KAWANA K, NAKATSUKA T, FUJII T: Embryotoxic effect of a class Ill anti-arrhythmic agent, L-691,121, in rats. Teratology (1992) 5:462.
   Google Scholar
• SPENCE SG, VETTER C, HOE CM: Effects of the class III anti-arrhythmic dofetilide (UK-68,798) on the heart rate of mid-gestation rat embryos, in vitro. Teratology (1994) 49:282–292.
   PubMedGoogle Scholar
• WEBSTER WS, BROWN-WOODMAN PD, SNOW MD, DANIELSSON BR: Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Teratology (1996) 53:168–175.
   PubMedGoogle Scholar
• SEDGEWICK MJ, RASMUSSEN HS, COBBE SM: Effect of anew class III anti-arrhythmic agent (UK-68798) on QT interval and heart rate. Br. Heart (1990) 64:96.
   Google Scholar